Motilal Oswal has reiterated its BUY rating on Glenmark Pharmaceuticals, setting a compelling price target of Rs 2,430—implying a robust 28% upside from current levels.

Glenmark Pharmaceuticals has seized the spotlight within India’s pharmaceutical landscape, propelled by a record-breaking global licensing agreement for its flagship oncology asset.

Morningstar has issued a BUY recommendation on CRISPR Therapeutics AG (NASDAQ: CRSP), underscoring the stock’s significant undervaluation and robust long-term prospects, in its latest research repo

Kotak Institutional Equities has issued a BUY recommendation for Syngene International, setting a fair value target of Rs 825 per share, a significant upside from its current market price of Rs 633

Prabhudas Lilladher has issued an “ACCUMULATE” recommendation on Torrent Pharmaceuticals (TRP), with a target price of Rs3,850 per share.

Kotak Institutional Equities has issued a BUY recommendation for Indegene, a leading IT services firm specializing in the healthcare and life sciences sectors, with a current marke